ArticleFrontiers in oncology2011
Born to be alive: a role for the BCL-2 family in melanoma tumor cell survival, apoptosis, and treatment.
Article in Frontiers in oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 54 citations in OpenAlex.
- CD24 flags anastasis in melanoma cells.Apoptosis : an international journal on programmed cell death · 2025Article
- Aptamer functionalized nucleic acid nano drug for targeted synergistic therapy for colon cancer.Journal of nanobiotechnology · 2023Article
- Therapeutic targeting of anoikis resistance in cutaneous melanoma metastasis.Frontiers in cell and developmental biology · 2023Review
- BCL-xL inhibition potentiates cancer therapies by redirecting the outcome of p53 activation from senescence to apoptosis.Cell reports · 2022Article
- Anti-cancer properties ofFrontiers in oncology · 2022Article
- Assessment of Betulinic Acid Cytotoxicity and Mitochondrial Metabolism Impairment in a Human Melanoma Cell Line.International journal of molecular sciences · 2021Article
- Inhibition of BCL2 Family Members Increases the Efficacy of Copper Chelation in BRAFCancer research · 2020Article
- Conjunctival Melanoma: Genetic and Epigenetic Insights of a Distinct Type of Melanoma.International journal of molecular sciences · 2019Review
- Systems biology-based investigation of cooperating microRNAs as monotherapy or adjuvant therapy in cancer.Nucleic acids research · 2019Review
- Mitochondrial transplantation regulates antitumour activity, chemoresistance and mitochondrial dynamics in breast cancer.Journal of experimental & clinical cancer research : CR · 2019Article
- Bayesian Hierarchical Varying-sparsity Regression Models with Application to Cancer Proteogenomics.Journal of the American Statistical Association · 2019Article
- SIRT1 Protects Against Apoptosis by Promoting Autophagy in the Oxygen Glucose Deprivation/Reperfusion-Induced Injury.Frontiers in neurology · 2019Article
- Spontaneously hypertensive rats are sensitive to thoracic aorta damage induced by a hot and humid environment.Experimental and therapeutic medicine · 2017Article
- Downregulation of microRNA-125a is involved in intervertebral disc degeneration by targeting pro-apoptotic Bcl-2 antagonist killer 1.Iranian journal of basic medical sciences · 2017Article
- Mitochondrial dynamics as regulators of cancer biology.Cellular and molecular life sciences : CMLS · 2017Review
- Protective Effects of Paeoniflorin Against MPP(+)-induced Neurotoxicity in PC12 Cells.Neurochemical research · 2016Article
- BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.Cancer medicine · 2016Article
- Article
- Anti-apoptotic BCL-2 proteins govern cellular outcome following B-RAF(V600E) inhibition and can be targeted to reduce resistance.Oncogene · 2015Article
- BCL-2 proteins: melanoma lives on the edge.Oncoscience · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
The global incidence of melanoma has dramatically increased during the recent decades, yet the advancement of primary and adjuvant therapies has not kept a similar pace. The development of melanoma is often centered on cellular signaling that hyper-activates survival pathways, while inducing a concomitant blockade to cell death. Aberrations in cell death signaling not only promote tumor survival and enhanced metastatic potential, but also create resistance to anti-tumor strategies. Chemotherapeutic agents target melanoma tumor cells by inducing a form of cell death called apoptosis, which is governed by the BCL-2 family of proteins.The BCL-2 family is comprised of anti-apoptotic proteins (e.g., BCL-2, BCL-xL, and MCL-1) and pro-apoptotic proteins (e.g., BAK, BAX, and BIM), and their coordinated regulation and function are essential for optimal responses to chemotherapeutics. Here we will discuss what is currently known about the mechanisms of BCL-2 family function with a focus on the signaling pathways that maintain melanoma tumor cell survival. Importantly, we will critically evaluate the literature regarding how chemotherapeutic strategies directly impact on BCL-2 family function and offer several suggestions for future regimens to target melanoma and enhance patient survival.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.